AVAGAST

AVAGAST. The AVAGAST trial was a pivotal international Phase III trial that evaluated the addition of the angiogenesis inhibitor Bevacizumab to standard Chemotherapy for patients with advanced Gastric cancer. Conducted across multiple countries, including the United States, South Korea, and several in Europe, it aimed to improve outcomes in a disease with a historically poor Prognosis. Although the primary endpoint was not met, the study generated significant insights into the molecular heterogeneity of gastric cancer and influenced the design of future Oncology trials.

Background and Rationale

Gastric cancer remains a leading cause of Cancer-related mortality worldwide, with particularly high incidence rates in regions like East Asia and Eastern Europe. For patients with metastatic or locally advanced disease, first-line treatment in the mid-2000s typically involved platinum-based regimens such as Cisplatin and fluoropyrimidines. Bevacizumab, a Monoclonal antibody targeting Vascular endothelial growth factor (VEGF), had demonstrated a survival benefit in other adenocarcinomas like Colorectal cancer and Non-small cell lung carcinoma. The rationale for AVAGAST was grounded in the strong pathophysiological role of Angiogenesis in Tumorigenesis, with preclinical evidence suggesting VEGF was overexpressed in gastric tumors. Promising results from an earlier Phase II trial, the AVF2107g study in Colorectal cancer, supported the investigation of this biologic agent in the gastric cancer setting.

Study Design and Methodology

AVAGAST was a global, randomized, double-blind, placebo-controlled study sponsored by F. Hoffmann-La Roche. It enrolled 774 patients with previously untreated, Inoperable locally advanced or metastatic Adenocarcinoma of the Stomach or Gastroesophageal junction. Patients were stratified by Region (Americas, Europe, Asia) and disease status. They were randomized to receive either Bevacizumab or a Placebo, both combined with a backbone chemotherapy regimen of Cisplatin and Capecitabine. The primary endpoint was Overall survival (OS), with key secondary endpoints including Progression-free survival (PFS), Overall response rate (ORR), and safety. The trial was conducted in accordance with Good Clinical Practice guidelines and the Declaration of Helsinki.

Results and Findings

The final results, published in the Journal of Clinical Oncology in 2011, showed that the addition of Bevacizumab to chemotherapy did not significantly improve the primary endpoint of Overall survival. The median OS was 12.1 months with the Bevacizumab combination versus 10.1 months with Placebo and chemotherapy. While this difference was not statistically significant, improvements were observed in the secondary endpoints of Progression-free survival and Overall response rate. The safety analysis indicated that the adverse event profile was consistent with the known effects of Bevacizumab, with increased rates of Hypertension, Bleeding, and Proteinuria noted in the experimental arm. These findings were presented at major conferences including the American Society of Clinical Oncology (ASCO) annual meeting.

Subgroup Analyses and Biomarker Data

A critical component of the AVAGAST analysis was the exploration of subgroup and biomarker data, which revealed substantial regional differences in outcomes. Patients enrolled in the Americas appeared to derive a greater potential benefit from Bevacizumab compared to those in Asia, particularly South Korea and Japan. Subsequent translational research investigated potential predictive biomarkers, including plasma levels of Vascular endothelial growth factor-A (VEGF-A) and Neuropilin expression. These analyses suggested that baseline VEGF-A levels might correlate with treatment efficacy, providing a Hypothesis for patient selection in future trials. The regional variation underscored the molecular and epidemiological diversity of gastric cancer across different populations.

Impact and Subsequent Research

Although AVAGAST did not meet its primary goal, it had a profound impact on the field of Gastrointestinal oncology. It highlighted the importance of geographic and molecular stratification in global Oncology trials. The biomarker findings directly influenced the design of the subsequent AVATAR trial in China and the RAINBOW trial, which investigated Ramucirumab, another anti-angiogenic agent targeting the VEGF receptor 2. The data also contributed to the scientific understanding of Tumor microenvironment and resistance mechanisms. Furthermore, the trial's methodology set a benchmark for future Phase III studies in Upper gastrointestinal cancer, informing the development of later successful regimens involving Immunotherapy agents like Pembrolizumab and Nivolumab. Category:Clinical trials in oncology Category:Gastric cancer Category:2011 in science